l carnitine and prostate cancer Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 CXCR4 pathways acetyl l carnitine androgen receptor
acetyl l carnitine androgen receptor Acetyl L Carnitine downregulates invasion (CXCR4 CXCL12, MMP 9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies Journal of Experimental L Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double Blind, Placebo Controlled Study ScienceDirect L Carnitine (tartrate) The mechanism of acetyl L carnitine on colorectal cancer and its metabolomic study ScienceDirect
Pay in 4 interest-free payments of $6.73 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



